Merck Reports Phase 3 KEYNOTE-789 Results for Keytruda in EGFR-Mutated NSCLC

Merck today announced results from the Phase 3 KEYNOTE-789 trial evaluating Keytruda (pembrolizumab) plus pemetrexed and platinum chemotherapy versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer who had progressed on EGFR tyrosine kinase inhibitor therapy. The trial did not meet its primary endpoints, providing insights into the role of immunotherapy in EGFR-mutated NSCLC.